Phases, active trials: Phase 1: 35, Phase 1/2: 22, Phase 2: 24, Phase 2/3: 11, Phase 3: 65, Phase 4: 8, No phase listed: 67
Bristol-Myers Squibb's clinical pipeline is defined by its foundational immuno-oncology franchise, Opdivo (nivolumab, PD-1) and Yervoy (ipilimumab, CTLA-4), plus a growing cell therapy portfolio. The Opdivo + Yervoy combination remains one of the most broadly applied IO regimens in oncology, with ongoing trials across virtually every solid tumor type. In hematology, Breyanzi (lisocabtagene maraleucel) for large B-cell lymphoma and Abecma (idecabtagene vicleucel) for multiple myeloma represent BMS's CAR-T franchise, with active trials moving these therapies into earlier lines. Their cardiovascular drug mavacamten (Camzyos) and factor XIa inhibitor milvexian are advancing in a rejuvenated cardiovascular pipeline.
- Immuno-oncology (PD-1/CTLA-4)
- Cell therapy (CAR-T, lymphoma, myeloma)
- Hematology / combinations
- Cardiovascular (mavacamten, factor XIa)
- Fibrosis / inflammation
- Opdivo (nivolumab): PD-1, pan-tumor IO
- Yervoy (ipilimumab): CTLA-4, IO combination
- Breyanzi (lisocabtagene maraleucel): CD19 CAR-T, B-cell lymphoma
- Abecma (idecabtagene vicleucel): BCMA CAR-T, myeloma
- Reblozyl (luspatercept): erythroid maturation, MDS/beta-thal
- Camzyos (mavacamten): cardiac myosin, HCM
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells NCT03435796 | Primary completion moved at least 6 years 5 months later | Recruiting |
14 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With… NCT05946941 | Nov 18, 2026 · Estimated | Phase 3 |
11 more on the Completions page. See the calendar →
Monitor the Bristol-Myers Squibb pipeline daily
Get a daily digest when Bristol-Myers Squibb registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| Multiple Myeloma | 13 |
| Healthy Volunteers | 12 |
| Schizophrenia | 9 |
| Melanoma | 7 |
| Non-Small Cell Lung Cancer | 6 |
| Plaque Psoriasis | 6 |
| Psoriasis | 6 |
| Advanced Solid Tumors | 5 |
BMS's PD-1/CTLA-4 combination program generates dozens of new combination trials annually. For any company developing new IO agents or solid tumor therapies, tracking when BMS starts a new Opdivo+Yervoy+X trial in your indication is critical competitive intelligence.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Bristol-Myers Squibb's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Bristol-Myers Squibb may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Bristol-Myers Squibb pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based… NCT07100080 | Recruiting | Interventions modified | 2026-11-13 |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for… NCT06937229 | Recruiting | Trial sites expanded: 252 → 255 locations | 2026-11-13 |
| A Study of KarXT + KarX-EC for Treatment of Irritability in Children and… NCT07284745 | Recruiting | Recruitment opened | 2026-11-11 |
| A Study of KarXT + KarX-EC for Treatment of Irritability in Children and… NCT07285798 | Recruiting | Start date changed from estimate of Oct 2, 2026 to Oct 6, 2026 | 2026-11-11 |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy… NCT06561386 | Recruiting | Trial sites expanded: 327 → 330 locations | 2026-11-10 |
Each trial page shows every change DataLookout has recorded for that trial.